| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Center for Research Resources (NCRR) |
| Information provided by: | National Center for Research Resources (NCRR) |
| ClinicalTrials.gov Identifier: | NCT00011141 |
Purpose
The etiology of immune-mediated diabetes mellitus (IMD) remains unclear. However, previous studies indicate that autoimmunity may be a result of dysfunction of natural killer T cells (NK-T cells). Newly diagnoses patients with IMD have been shown in our laboratory to have significantly lower NK-T cells than normal controls. Other studies have shown that oral administration of lactobacillus can boost NK-T cell activity in children with HIV without side effects. Our objective is to evaluate the effect of lactobacillus administration on NK-T cell activity in patients with IMD
| Condition | Intervention |
|
Diabetes Mellitus |
Drug: Oral lactobacillus administration |
| MedlinePlus related topics: | Diabetes |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study |
| Official Title: | Lactobacillus Plantarum as Therapy for NK-T Cell Deficiency |
Eligibility
| Ages Eligible for Study: | 1 Year to 95 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Recently diagnosed (within the last 6 months) patients with immune-mediated (type 1) diabetes
Contacts and Locations More Information
| Study ID Numbers: | NCRR-M01RR06020-0165 |
| First Received: | February 12, 2001 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00011141 |
| Health Authority: | United States: Federal Government |
|
|
|
|
